Fig. 5
Viability and CD26 surface levels in late passage MSC(AT) decrease following senolytic treatment. A Cell viability of late passage MSC(AT) that were either treated with DMSO (vehicle control) or a senolytic: NAVI: navitoclax (20 μM), QUER: quercetin (+:400 and ++:800 μM) and DMAG: 17-DMAG (+:25.6 and ++:51.2 μM). B CD26 gMFI and C %CD26high MSCs among living MSC(AT). [n = 4 adult and 1 pediatric LP-MSC(AT)]. Data presented as mean ± SD, comparisons done with paired one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001